series-b
Stage
3
Investors
About
Cybrexa Therapeutics develops tumor-targeting peptide-drug conjugates using its antigen-independent alphalex™ platform to deliver potent anticancer agents directly into tumor cells, aiming to improve cancer treatment outcomes.
Explore Cybrexa's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.